https://www.phreesia.net/z2/patient/Payment.aspx/Start?encrypted=PmUx0k5lthSgT5jGeQm3Nz60Ratjfnm4V1MZr9P2KypIgLUnDP5Q5B2sHXNP6_Ddb3_H2MXc9cJl6L8VtSsrzJkZ2TX9iWxHWxfhzSujImSUxPII38pXHriFf7MdF6qhjuqYGzQAoA1BtGPom1E1FJ8LT5joNU6nfWZywoRY11g1

Research

 

Clinical Trials

Treatment of retinal diseases is a rapidly changing field of medicine with new techniques and procedures being developed every year. Southwest Retina Specialists has been involved with research over the last six years for a variety of retina conditions, including Diabetic Macular Edema, Vitreous Hemorrhage with surgical intervention, and Age-Related Macular Degeneration.

While clinical trials are always voluntary, to qualify, patients need to go through a screening process prior to enrollment. Each studies eligibility and criteria vary.

Please contact one of our study coordinators, Kasey Dalrymple or Rachel Barbee at 806-351-1870 (ext. 1113 or ext. 1148) if you are interested in being screened or want more information on a clinical trial being conducted.

You can learn more about each trial and how to participate in a clinical trial at:
http://www.ClinicalTrials.gov
http://www.fda.gov

 


Current Studies, Open for Enrollment

To be determined, current as of 09/Sep/2022



Ongoing Studies (Closed Enrollment)


GLOW

Moderate Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR) (Ongoing, Actively Recruiting)
Kodiak Sciences

This is a Phase 3, prospective, randomized, double-masked, sham-controlled, two-arm, multicenter study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).

  • ClinicalTrials.gov Identifier: NCT05066230
  • Sponsor: Kodiak Sciences Inc
  • Site: Southwest Retina Specialist, Amarillo, TX.

DAYLIGHT

Neovascular (Wet) Age Related Macular Degeneration (Ongoing, Closed Enrollment)

Kodiak Sciences
This is a Phase 3, prospective, randomized, double-masked, two-arm, multi-center non-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg in participants with visual impairment due to treatment-naïve neovascular (wet) age-related macular degeneration (wAMD)

  • ClinicalTrials.gov Identifier: NCT04964089
  • Sponsor: Kodiak Sciences Inc
  • Site: Southwest Retina Specialist, Amarillo, TX.

GATHER2

Geographic Atrophy Secondary to Age-Related Macular Degeneration (Ongoing, Not Recruiting)

IVERIC BIO (ISEE2008)

A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

  • ClinicalTrials.gov Identifier: NCT04435366
  • Sponsor: IVERIC BIO (ISEE2008)
  • Site: Southwest Retina Specialist, Amarillo, TX.

GLEAM

Treatment-Naïve DME.(Ongoing, Closed Enrollment)

Kodiak Sciences

This is a Phase 3, prospective, randomized, double-masked, two-arm, multi-center non-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg in participants with treatment-naïve DME.

  • ClinicalTrials.gov Identifier: NCT04611152
  • Sponsor: Kodiak Sciences Inc
  • Site: Southwest Retina Specialist, Amarillo, TX.